Provided by Tiger Fintech (Singapore) Pte. Ltd.

Oculis

19.57
-0.0700-0.36%
Post-market: 19.18-0.3900-1.99%17:52 EDT
Volume:51.97K
Turnover:1.02M
Market Cap:918.71M
PE:-8.35
High:19.84
Open:19.20
Low:19.20
Close:19.64
Loading ...

Why TransMedics Fell 15.7% This Week

Motley Fool
·
17 Jan

Why TransMedics Group Stock Is Tanking Today

Motley Fool
·
10 Jan

TransMedics Shares Plunge Following Short Seller Allegations

GuruFocus
·
10 Jan

2 MedTech Stocks That Are Screaming Buys in January

Motley Fool
·
10 Jan

Promising Clinical Results and Market Potential Drive Buy Rating for Oculis Holding

TIPRANKS
·
07 Jan

Oculis price target raised to $31 from $23 at BofA

TIPRANKS
·
07 Jan

Oculis Trial Shows Potential for Optical Neuroprotective Therapy

Exec Edge
·
07 Jan

Oculis Holding’s OCS-05 Shows Promising Results in Phase 2 Trial for Acute Optic Neuritis

TIPRANKS
·
07 Jan

Oculis Holding Price Target Maintained With a $30.00/Share by HC Wainwright & Co.

Dow Jones
·
07 Jan

Oculis Holding’s OCS-05 Receives Buy Rating Amid Promising Clinical Data and Regulatory Advancements

TIPRANKS
·
07 Jan

Bank of America Securities Sticks to Their Buy Rating for Oculis Holding (OCS)

TIPRANKS
·
06 Jan

1 Super Growth Stock Down 63% to Buy Hand Over Fist in 2025

Motley Fool
·
06 Jan

BUZZ-Oculis climbs on positive mid-stage trial for eye treatment

Reuters
·
06 Jan

Oculis Holding Says Phase 2 Trial of Acute Optic Neuritis Therapy Met Primary Safety Endpoint

MT Newswires Live
·
06 Jan

Oculis Announces Positive OCS-05 Phase 2 ACUITY Trial in Acute Optic Neuritis, Met Primary Safety Endpoint and Key Secondary Efficacy Endpoints Opening Development Pathways as a Potential First-in-Class Neuroprotective Therapy

GlobeNewswire
·
06 Jan

Oculis Publishes Notification of Major Changes in Voting Rights

GlobeNewswire
·
04 Jan